| A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel M Cornberg, HA Razavi, A Alberti, E Bernasconi, M Buti, C Cooper, ... Liver International 31, 30-60, 2011 | 566 | 2011 |
| Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype RB Ray, LM Lagging, K Meyer, R Ray Journal of Virology 70 (7), 4438-4443, 1996 | 514 | 1996 |
| Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 … E Lawitz, E Gane, B Pearlman, E Tam, W Ghesquiere, D Guyader, L Alric, ... The Lancet 385 (9973), 1075-1086, 2015 | 366 | 2015 |
| Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients J Westin, H Nordlinder, M Lagging, G Norkrans, R Wejstål Journal of hepatology 37 (6), 837-842, 2002 | 366 | 2002 |
| Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein RB Ray, LM Lagging, K Meyer, R Steele, R Ray Virus research 37 (3), 209-220, 1995 | 350 | 1995 |
| Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ... The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017 | 267 | 2017 |
| Interferon (IFN)–γ–inducible protein–10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-α2a and ribavirin for chronic … AI Romero, M Lagging, J Westin, AP Dhillon, LB Dustin, JM Pawlotsky, ... The Journal of infectious diseases 194 (7), 895-903, 2006 | 265 | 2006 |
| Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection J Westin, LM Lagging, R Wejstål, G Norkrans, AP Dhillon Liver 19 (3), 183-187, 1999 | 257 | 1999 |
| IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection M Lagging, AI Romero, J Westin, G Norkrans, AP Dhillon, JM Pawlotsky, ... Hepatology 44 (6), 1617-1625, 2006 | 251 | 2006 |
| Immune responses to plasmid DNA encoding the hepatitis C virus core protein LM Lagging, K Meyer, D Hoft, M Houghton, RB Belshe, R Ray Journal of virology 69 (9), 5859-5863, 1995 | 222 | 1995 |
| Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection J Westin, LM Lagging, F Spak, N Aires, E Svensson, M Lindh, AP Dhillon, ... Journal of viral hepatitis 9 (3), 235-241, 2002 | 210 | 2002 |
| Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers S Islam, L Antonsson, J Westin, M Lagging Scandinavian journal of gastroenterology 40 (7), 867-872, 2005 | 209 | 2005 |
| Randomized comparison of 12 or 24 weeks of peginterferon α‐2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection M Lagging, N Langeland, C Pedersen, M Färkkilä, MR Buhl, K Mørch, ... Hepatology 47 (6), 1837-1845, 2008 | 205 | 2008 |
| International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C S Zeuzem, JM Pawlotsky, E Lukasiewicz, M Von Wagner, I Goulis, Y Lurie, ... Journal of hepatology 43 (2), 250-257, 2005 | 187 | 2005 |
| Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms M Lagging, G Askarieh, F Negro, S Bibert, J Söderholm, J Westin, M Lindh, ... PloS one 6 (2), e17232, 2011 | 185 | 2011 |
| Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus LM Lagging, K Meyer, RJ Owens, R Ray Journal of virology 72 (5), 3539-3546, 1998 | 176 | 1998 |
| Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic … G Askarieh, Å Alsiö, P Pugnale, F Negro, C Ferrari, AU Neumann, ... Hepatology 51 (5), 1523-1530, 2010 | 150 | 2010 |
| Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C PDC Leutscher, M Lagging, MR Buhl, C Pedersen, G Norkrans, ... Hepatology 52 (2), 430-435, 2010 | 135 | 2010 |
| IL28B polymorphisms, IP‐10 and viral load predict virological response to therapy in chronic hepatitis C G Fattovich, L Covolo, S Bibert, G Askarieh, M Lagging, S Clément, ... Alimentary pharmacology & therapeutics 33 (10), 1162-1172, 2011 | 131 | 2011 |
| Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial H Orlent, BE Hansen, M Willems, JT Brouwer, R Huber, GA Kullak-Ublick, ... Journal of hepatology 45 (4), 539-546, 2006 | 120 | 2006 |
Bart L. HaagmansDepartment of Viroscience, Erasmus MC, RotterdamVerifierad e-postadress på erasmusmc.nl
